Euroopan unioni - suomi - EMA (European Medicines Agency)

n.v. organon - asenapine (as maleate)  - kaksisuuntainen mielialahäiriö - psyykenlääkkeiden - sycrest on tarkoitettu kohtalaisen vaikeisiin mania-episodeihin, jotka liittyvät bipolaariseen i -häiriöön aikuisilla.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - sian sirkoviruksen tyypin 2 orf2-proteiini - immunologiset suidaeille - siat - aktiivinen immunisointi siat, joilla ei ole pcv2 emolle saatujen vasta-iästä alkaen 2 viikkoa vastaan sian sirkovirus tyyppi 2 (pcv2),.

Euroopan unioni - suomi - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - siat - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Euroopan unioni - suomi - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastiset aineet - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

teva b.v. - tiotropium bromide monohydrate - inhalaatiojauhe, kapseli, kova - 10 mikrog/ vapautunut annos - tiotropiumbromidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

pfizer oy pfizer oy - medroxyprogesteroni acetas - injektioneste, suspensio - 104 mg - medroksiprogesteroni

Suomi - suomi - Fimea (Suomen lääkevirasto)

aristo pharma gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 100 mg - imatinibi

Suomi - suomi - Fimea (Suomen lääkevirasto)

aristo pharma gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 400 mg - imatinibi

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellitus, johon tarvitaan insuliinin hoitoa. insulin human winthrop rapid soveltuu myös hyperglykeemisen kooman ja ketoasidoosin hoitoon sekä diabetes mellituspotilaille ennalta, sisäisestä ja postoperatiivisesta vakautumisesta.